|
시장보고서
상품코드
1625428
오피오이드 시장 : 규모, 점유율, 동향, 산업 분석 보고서-클래스별, 제품별, 방출 유형별, 용도별, 지역별-시장 예측(2025-2034년)Opioid Market Size, Share, Trends, Industry Analysis Report: By Class, Product, Release Type, Application, and Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계의 오피오이드 시장 규모는 2034년까지 284억 5,000만 달러에 이를 것으로 예상됩니다. 이 보고서는 현재 시장 역학을 상세하게 파악하고 미래 시장 성장에 대한 분석을 제공합니다.
오피오이드 시장의 성장은 기업 간의 파트너십 증가로 인한 것입니다. 제약회사, 의료제공업체, 연구기관의 제휴는 오피오이드 요법의 새로운 제제와 개선된 전달 시스템의 개발을 촉진하고 있습니다. 이러한 제휴를 통해 기업은 자원을 결합하고 전문 지식을 활용하고 연구개발 프로세스를 가속화할 수 있으므로 효과적인 통증 관리 솔루션을 더 빠르게 시장에 출시할 수 있습니다. 또한, 전략적 제휴는 유통망을 개선하고, 특히 충분한 서비스를 받지 않은 지역에서 오피오이드 치료제에 대한 접근을 확대합니다. 안전에 대한 우려와 법규의 준수 등 오피오이드 처방과 관련된 과제를 해결하기 위해 각 회사가 손을 잡으면 통증 관리에 대한 보다 종합적인 접근이 촉진되고 궁극적으로 시장에서 오피오이드의 존재감이 강해집니다.
외상 유병률 증가는 효과적인 통증 관리의 필요성 때문에 오피오이드 시장 수요를 크게 견인하고 있습니다. 미국에서는 연간 약 150만 건의 외상성 뇌손상 사례가 보고되고 있으며, 그 대부분은 입원과 장기 통증 관리가 필요합니다. CDC는 이러한 경우의 회복에 통증 관리가 필수적이며 오피오이드 수요를 증가시킬 것이라고 강조합니다. 또한, 외상성 뇌 손상의 장기적인 영향에 대한 의식 증가는 종합적인 통증 전략의 필요성을 강조하고 오피오이드 처방의 추가 증가로 이어질 것으로 예상됩니다. 그 결과, 오피오이드 시장 규모는 향후 수년간 확대될 전망입니다.
오피오이드 시장은 통증 관리에 대한 인식과 교육 증가로 확대되고 있습니다. 환자와 건강 관리 제공업체 모두 이용 가능한 다양한 치료 옵션을 이해하고 있습니다. 미국에서는 약 5,000만 명의 성인이 만성 통증으로 고통받고 있습니다. 의료 가이드라인이 업데이트됨에 따라 의사는 오피오이드를 처방할 때 자신감을 갖게 되며, 통증 관리를 위해 오피오이드를 적절히 사용하게 되었습니다. 이러한 통증 치료의 선택에 대한 이해 증가는 만성 통증 관리에서 오피오이드 사용 증가에 기여합니다.
오피오이드 시장 보고서 하이라이트
방출 유형별로는 방출 연장형 및 장시간 작용형 오피오이드의 분야가 예측 기간 중에 세계 시장에서 대폭적인 CAGR의 성장을 이룰 것으로 예측되고 있습니다. 이러한 성장은 장기간 작용하는 오피오이드를 필요로 하는 장기간 통증 및 외상 유병률 증가에 기인합니다.
용도별로 만성 및 급성 부상 증가로 통증 관리 분야가 2024년 시장에서 가장 큰 수익 점유율을 차지했습니다.
2024년에는 북미가 오피오이드 세계 시장 점유율을 독점했는데, 이는 병원 수가 증가함에 따라 처방율이 상승하고 있기 때문입니다.
인도의 오피오이드 시장은 자금 조달과 해외 직접 투자 유입 증가로 인해 상당한 성장이 예상됩니다.
세계 주요 시장 기업으로는 Aurobindo Pharma Limited; Assertio Therapeutics, Inc.; AbbVie Inc.; Actavis Plc.; Amneal Pharmaceuticals LLC; Boehringer Ingelheim International GmbH; Cadila Healthcare Limited; Fresenius Kabi; LLC; Purdue Pharma LP; Pfizer Inc.; Rhodes Pharmaceuticals LP; Sun Pharmaceutical Industries Limited; Trevena Inc.; Teva Pharmaceutical Industries Ltd.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 오피오이드 시장 인사이트
- 시장 현황
- 오피오이드 시장 역학
- 성장 촉진요인 및 기회
- 외상성 상해 증가가 시장 규모의 확대 견인
- 의료 인프라 확장에 대한 투자 증가가 시장 성장 견인
- 억제요인 및 과제
- 엄격한 정부규제
- 성장 촉진요인 및 기회
- PESTEL 분석
- 오피오이드 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 오피오이드 시장 : 클래스별
- 주요 조사 결과
- 서문
- 자연
- 반합성
- 완전 합성
제6장 세계의 오피오이드 시장 : 제품별
- 주요 조사 결과
- 서문
- 코데인
- 펜타닐
- 옥시코돈
- 메사돈
- 모르핀
- 히드로코돈
- 트라마돌
- 프로폭시펜
- 기타
제7장 세계의 오피오이드 시장 : 방출 유형별
- 주요 조사 결과
- 서문
- 즉효성 및 단시간작용형 오피오이드
- 서방형 및 장시간 작용형 오피오이드
제8장 세계의 오피오이드 시장 : 용도별
- 주요 조사 결과
- 서문
- 통증 관리
- 암 통증
- 기침 치료
- 진통제
- 설사의 치료
- 중독으로부터의 탈각
- 기타
제9장 세계의 오피오이드 시장 : 지역별
- 주요 조사 결과
- 서문
- 오피오이드 시장 평가 : 지역별(2020-2034년)
- 북미
- 북미 : 클래스별(2020-2034년)
- 북미 : 제품별(2020-2034년)
- 북미 : 방출 유형별(2020-2034년)
- 북미 : 용도별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 클래스별(2020-2034년)
- 유럽 : 제품별(2020-2034년)
- 유럽 : 방출 유형별(2020-2034년)
- 유럽 : 용도별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 클래스별(2020-2034년)
- 아시아태평양 : 제품별(2020-2034년)
- 아시아태평양 : 방출 유형별(2020-2034년)
- 아시아태평양 : 용도별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 클래스별(2020-2034년)
- 중동 및 아프리카 : 제품별(2020-2034년)
- 중동 및 아프리카 : 방출 유형별(2020-2034년)
- 중동 및 아프리카 : 용도별(2020-2034년)
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 클래스별(2020-2034년)
- 라틴아메리카 : 제품별(2020-2034년)
- 라틴아메리카 : 방출 유형별(2020-2034년)
- 라틴아메리카 : 용도별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴, 협업, 합의 및 공개
제11장 기업 프로파일
- Aurobindo Pharma Limited
- Assertio Therapeutics, Inc.
- AbbVie Inc.
- Actavis Plc.
- Amneal Pharmaceuticals LLC
- Boehringer Ingelheim International GmbH
- Cadila Healthcare Limited
- Fresenius Kabi
- Mallinckrodt Pharmaceuticals
- Endo International plc
- Johnson & Johnson Corporation
- Lupin Limited
- Nesher Pharmaceuticals LLC
- Purdue Pharma LP
- Pfizer Inc.
- Rhodes Pharmaceuticals LP
- Sun Pharmaceutical Industries Limited
- Trevena Inc.
- Teva Pharmaceutical Industries Ltd.
The global opioid market size is expected to reach USD 28.45 billion by 2034, according to a new study by Polaris Market Research. The report "Opioid Market Size, Share, Trends, Industry Analysis Report: By Class, Product, Release Type (Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid), Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The opioid market growth is attributed to an increase in partnerships between companies. Collaborations between pharmaceutical firms, healthcare providers, and research institutions are facilitating the development of new formulations and improved delivery systems for opioid therapies. These alliances enable organizations to combine resources, leverage expertise, and expedite the research and development process, allowing for faster introduction of effective pain management solutions to the market. Additionally, strategic partnerships improve distribution networks and expand access to opioid medications, particularly in underserved areas. Companies join forces to address challenges related to opioid prescribing such as safety concerns and regulatory compliance; they are promoting a more holistic approach to pain management, ultimately strengthening the presence of opioids in the market.
The rising prevalence of traumatic injuries significantly drives opioid market demand due to the need for effective pain management. The US reports around 1.5 million traumatic brain injury cases annually, with many requiring hospitalization and long-term pain management. The CDC highlights that pain management is essential for recovery in these cases, increasing the demand for opioids. Additionally, heightened awareness of the long-term effects of TBIs emphasizes the necessity for comprehensive pain strategies, further leading to an expected rise in opioid prescriptions. Consequently, the opioid market size is poised for growth in the projected years.
The opioid market is expanding due to increased awareness and education about pain management. Both patients and healthcare providers are learning more about the different treatment options available. In the United States, nearly 50 million adults suffer from chronic pain. Updated medical guidelines are helping doctors feel more confident when prescribing opioids, ensuring they are used properly to manage pain. This growing understanding of pain treatment options is contributing to the rise in the use of opioids for managing chronic pain.
Opioid Market Report Highlights
By release type, the extended-release/long-acting opioid segment is anticipated to experience substantial growth at a significant CAGR in the global market during the forecast period. This growth is attributed to an increase in the prevalence of extended pain and traumatic injuries requiring long-acting opioids.
The pain management segment, by application, accounted for the largest revenue share of the market in 2024 due to the rising number of chronic and acute injuries.
In 2024, North America dominated the global opioid market share due to the increasing number hospitals, leading to the increase in prescription rate.
The opioid market in India is projected for substantial growth due to the increasing funding and foreign direct investment inflow.
A few global key market players are Aurobindo Pharma Limited; Assertio Therapeutics, Inc.; AbbVie Inc.; Actavis Plc.; Amneal Pharmaceuticals LLC; Boehringer Ingelheim International GmbH; Cadila Healthcare Limited; Fresenius Kabi; Mallinckrodt Pharmaceuticals; Endo International plc; Johnson & Johnson Corporation; Lupin Limited; Nesher Pharmaceuticals LLC; Purdue Pharma L.P.; Pfizer Inc.; Rhodes Pharmaceuticals L.P.; Sun Pharmaceutical Industries Limited; Trevena Inc.; Teva Pharmaceutical Industries Ltd.
Polaris Market Research has segmented the opioid market report on the basis of class, product, release type, application, and region:
By Class Outlook (Revenue - USD Billion, 2020-2034)
- § Natural
- § Semi-Synthetic
- § Fully Synthetic
By Product Outlook (Revenue - USD Billion, 2020-2034)
- § Codeine
- § Fentanyl
- § Oxycodone
- § Methadone
- § Morphine
- § Hydrocodone
- § Tramadol
- § Propoxyphene
- § Others
By Release Type Outlook (Revenue - USD Billion, 2020-2034)
- § Immediate-Release/Short-Acting Opioid
- § Extended-Release/Long-Acting Opioid
- By Application (Revenue - USD Billion, 2020-2034)
- § Pain Management
- § Neuropathic
- § Migraine
- § Orthopedic and Musculoskeletal
- § Arthritis
- § Fibromyalgia
- § Others
- § Cancer Pain
- § Brain
- § Breast
- § Colorectal
- § Blood
- § Skin
- § Prostate
- § Others
- § Cough Treatment
- § Analgesia
- § Diarrhea Treatment
- § De-addiction
- § Others
By Regional Outlook (Revenue - USD Billion, 2020-2034)
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Opioid Market Insights
- 4.1. Opioid Market - Market Snapshot
- 4.2. Opioid Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Prevalence of Traumatic Injuries is Driving the Market Size
- 4.2.1.2. Increasing Investment for Expansion of Medical Infrastructure Are Driving the Market Growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Stringent Government Regulation
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Opioid Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Opioid Market, by Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Opioid Market, by Class, 2020-2034 (USD billion)
- 5.3. Natural
- 5.3.1. Global Opioid Market, by Natural, by Region, 2020-2034 (USD billion)
- 5.4. Semi-synthetic
- 5.4.1. Global Opioid Market, by Semi-synthetic, by Region, 2020-2034 (USD billion)
- 5.5. Fully synthetic
- 5.5.1. Global Opioid Market, by Fully synthetic, by Region, 2020-2034 (USD billion)
6. Global Opioid Market, by Product
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Opioid Market, by Product, 2020-2034 (USD billion)
- 6.3. Codeine
- 6.3.1. Global Opioid Market, by Codeine, by Region, 2020-2034 (USD billion)
- 6.4. Fentanyl
- 6.4.1. Global Opioid Market, by Fentanyl, by Region, 2020-2034 (USD billion)
- 6.5. Oxycodone
- 6.5.1. Global Opioid Market, by Oxycodone, by Region, 2020-2034 (USD billion)
- 6.6. Methadone
- 6.6.1. Global Opioid Market, by Methadone, by Region, 2020-2034 (USD billion)
- 6.7. Morphine
- 6.7.1. Global Opioid Market, by Morphine, by Region, 2020-2034 (USD billion)
- 6.8. Hydrocodone
- 6.8.1. Global Opioid Market, by Hydrocodone, by Region, 2020-2034 (USD billion)
- 6.9. Tramadol
- 6.9.1. Global Opioid Market, by Tramadol, by Region, 2020-2034 (USD billion)
- 6.10. Propoxyphene
- 6.10.1. Global Opioid Market, by Propoxyphene, by Region, 2020-2034 (USD billion)
- 6.11. Others
- 6.11.1. Global Opioid Market, by Others, by Region, 2020-2034 (USD billion)
7. Global Opioid Market, by Release Type
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Opioid Market, by Release Type, 2020-2034 (USD billion)
- 7.3. Immediate-release/Short-acting opioid
- 7.3.1. Global Opioid Market, by Immediate-release/Short-acting opioid by Region, 2020-2034 (USD billion)
- 7.4. Extended-release/Long-acting opioid
- 7.4.1. Global Opioid Market, by Extended-release/Long-acting opioid, by Region, 2020-2034 (USD billion)
8. Global Opioid Market, by Application
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Opioid Market, by Application, 2020-2034 (USD billion)
- 8.3. Pain Management
- 8.3.1. Global Opioid Market, by Pain Management, by Region, 2020-2034 (USD billion)
- 8.3.2. Neuropathic
- 8.3.2.1. Global Opioid Market, by Neuropathic, by Region, 2020-2034 (USD billion)
- 8.3.3. Migraine
- 8.3.3.1. Global Opioid Market, by Migraine, by Region, 2020-2034 (USD billion)
- 8.3.4. Orthopedic and Musculoskeletal
- 8.3.4.1. Global Opioid Market, by Orthopedic and Musculoskeletal, by Region, 2020-2034 (USD billion)
- 8.3.5. Arthritis
- 8.3.5.1. Global Opioid Market, by Arthritis, by Region, 2020-2034 (USD billion)
- 8.3.6. Fibromyalgia
- 8.3.6.1. Global Opioid Market, by Fibromyalgia, by Region, 2020-2034 (USD billion)
- 8.3.7. Others
- 8.3.7.1. Global Opioid Market, by Others, by Region, 2020-2034 (USD billion)
- 8.4. Cancer Pain
- 8.4.1. Global Opioid Market, by Cancer Pain, by Region, 2020-2034 (USD billion)
- 8.4.2. Brain
- 8.4.2.1. Global Opioid Market, by Brain, by Region, 2020-2034 (USD billion)
- 8.4.3. Breast
- 8.4.3.1. Global Opioid Market, by Breast, by Region, 2020-2034 (USD billion)
- 8.4.4. Colorectal
- 8.4.4.1. Global Opioid Market, by Colorectal, by Region, 2020-2034 (USD billion)
- 8.4.5. Blood
- 8.4.5.1. Global Opioid Market, by Blood, by Region, 2020-2034 (USD billion)
- 8.4.6. Skin
- 8.4.6.1. Global Opioid Market, by Skin, by Region, 2020-2034 (USD billion)
- 8.4.7. Prostate
- 8.4.7.1. Global Opioid Market, by Prostate, by Region, 2020-2034 (USD billion)
- 8.4.8. Others
- 8.4.8.1. Global Opioid Market, by Others, by Region, 2020-2034 (USD billion)
- 8.5. Cough treatment
- 8.5.1. Global Opioid Market, by Cough treatment, by Region, 2020-2034 (USD billion)
- 8.6. Analgesia
- 8.6.1. Global Opioid Market, by Analgesia, by Region, 2020-2034 (USD billion)
- 8.7. Diarrhea treatment
- 8.7.1. Global Opioid Market, by Diarrhea treatment, by Region, 2020-2034 (USD billion)
- 8.8. De-addiction
- 8.8.1. Global Opioid Market, by De-addiction, by Region, 2020-2034 (USD billion)
- 8.9. Others
- 8.9.1. Global Opioid Market, by Others, by Region, 2020-2034 (USD billion)
9. Global Opioid Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Opioid Market Assessment, By Geography, 2020-2034 (USD billion)
- 9.3. Opioid Market - North America
- 9.3.1. North America: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.3.2. North America: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.3.3. North America: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.3.4. North America: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.3.5. Opioid Market - U.S.
- 9.3.5.1. U.S.: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.3.5.2. U.S.: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.3.5.3. U.S.: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.3.5.4. U.S.: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.3.6. Opioid Market - Canada
- 9.3.6.1. Canada: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.3.6.2. Canada: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.3.6.3. Canada: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.3.6.4. Canada: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4. Opioid Market - Europe
- 9.4.1. Europe: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.2. Europe: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.3. Europe: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.4. Europe: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4.5. Opioid Market - UK
- 9.4.5.1. UK: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.5.2. UK: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.5.3. UK: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.5.4. UK: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4.6. Opioid Market - France
- 9.4.6.1. France: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.6.2. France: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.6.3. France: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.6.4. France: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4.7. Opioid Market - Germany
- 9.4.7.1. Germany: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.7.2. Germany: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.7.3. Germany: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.7.4. Germany: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4.8. Opioid Market - Italy
- 9.4.8.1. Italy: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.8.2. Italy: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.8.3. Italy: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.8.4. Italy: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4.9. Opioid Market - Spain
- 9.4.9.1. Spain: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.9.2. Spain: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.9.3. Spain: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.9.4. Spain: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4.10. Opioid Market - Netherlands
- 9.4.10.1. Netherlands: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.10.2. Netherlands: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.10.3. Netherlands: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.10.4. Netherlands: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4.11. Opioid Market - Russia
- 9.4.11.1. Russia: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.11.2. Russia: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.11.3. Russia: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.11.4. Russia: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.4.12. Opioid Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.4.12.2. Rest of Europe: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.4.12.3. Rest of Europe: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.4.12.4. Rest of Europe: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5. Opioid Market - Asia Pacific
- 9.5.1. Asia Pacific: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.2. Asia Pacific: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.3. Asia Pacific: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.4. Asia Pacific: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5.5. Opioid Market - China
- 9.5.5.1. China: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.5.2. China: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.5.3. China: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.5.4. China: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5.6. Opioid Market - India
- 9.5.6.1. India: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.6.2. India: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.6.3. India: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.6.4. India: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5.7. Opioid Market - Malaysia
- 9.5.7.1. Malaysia: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.7.2. Malaysia: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.7.3. Malaysia: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.7.4. Malaysia: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5.8. Opioid Market - Japan
- 9.5.8.1. Japan: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.8.2. Japan: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.8.3. Japan: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.8.4. Japan: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5.9. Opioid Market - Indonesia
- 9.5.9.1. Indonesia: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.9.2. Indonesia: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.9.3. Indonesia: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.9.4. Indonesia: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5.10. Opioid Market - South Korea
- 9.5.10.1. South Korea: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.10.2. South Korea: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.10.3. South Korea: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.10.4. South Korea: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5.11. Opioid Market - Australia
- 9.5.11.1. Australia: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.11.2. Australia: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.11.3. Australia: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.11.4. Australia: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.5.12. Opioid Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.5.12.2. Rest of Asia Pacific: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.5.12.3. Rest of Asia Pacific: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.5.12.4. Rest of Asia Pacific: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.6. Opioid Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.6.2. Middle East & Africa: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.6.3. Middle East & Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.6.4. Middle East & Africa: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.6.5. Opioid Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.6.5.2. Saudi Arabia: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.6.5.3. Saudi Arabia: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.6.5.4. Saudi Arabia: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.6.6. Opioid Market - UAE
- 9.6.6.1. UAE: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.6.6.2. UAE: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.6.6.3. UAE: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.6.6.4. UAE: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.6.7. Opioid Market - Israel
- 9.6.7.1. Israel: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.6.7.2. Israel: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.6.7.3. Israel: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.6.7.4. Israel: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.6.8. Opioid Market - South Africa
- 9.6.8.1. South Africa: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.6.8.2. South Africa: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.6.8.3. South Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.6.8.4. South Africa: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.6.9. Opioid Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.6.9.2. Rest of Middle East & Africa: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.6.9.3. Rest of Middle East & Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.6.9.4. Rest of Middle East & Africa: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.7. Opioid Market - Latin America
- 9.7.1. Latin America: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.7.2. Latin America: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.7.3. Latin America: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.7.4. Latin America: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.7.5. Opioid Market - Mexico
- 9.7.5.1. Mexico: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.7.5.2. Mexico: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.7.5.3. Mexico: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.7.5.4. Mexico: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.7.6. Opioid Market - Brazil
- 9.7.6.1. Brazil: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.7.6.2. Brazil: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.7.6.3. Brazil: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.7.6.4. Brazil: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.7.7. Opioid Market - Argentina
- 9.7.7.1. Argentina: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.7.7.2. Argentina: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.7.7.3. Argentina: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.7.7.4. Argentina: Opioid Market, by Application, 2020-2034 (USD billion)
- 9.7.8. Opioid Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Opioid Market, by Class, 2020-2034 (USD billion)
- 9.7.8.2. Rest of Latin America: Opioid Market, by Product, 2020-2034 (USD billion)
- 9.7.8.3. Rest of Latin America: Opioid Market, by Release Type, 2020-2034 (USD billion)
- 9.7.8.4. Rest of Latin America: Opioid Market, by Application, 2020-2034 (USD billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Aurobindo Pharma Limited
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Assertio Therapeutics, Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. AbbVie Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Actavis Plc.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Amneal Pharmaceuticals LLC
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Boehringer Ingelheim International GmbH
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Cadila Healthcare Limited
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Fresenius Kabi
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Mallinckrodt Pharmaceuticals
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Endo International plc
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Johnson & Johnson Corporation
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Lupin Limited
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
- 11.13. Nesher Pharmaceuticals LLC
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
- 11.14. Purdue Pharma L.P.
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development
- 11.15. Pfizer Inc.
- 11.15.1. Company Overview
- 11.15.2. Financial Performance
- 11.15.3. Product Benchmarking
- 11.15.4. Recent Development
- 11.16. Rhodes Pharmaceuticals L.P.
- 11.16.1. Company Overview
- 11.16.2. Financial Performance
- 11.16.3. Product Benchmarking
- 11.16.4. Recent Development
- 11.17. Sun Pharmaceutical Industries Limited
- 11.17.1. Company Overview
- 11.17.2. Financial Performance
- 11.17.3. Product Benchmarking
- 11.17.4. Recent Development
- 11.18. Trevena Inc.
- 11.18.1. Company Overview
- 11.18.2. Financial Performance
- 11.18.3. Product Benchmarking
- 11.18.4. Recent Development
- 11.19. Teva Pharmaceutical Industries Ltd.
- 11.19.1. Company Overview
- 11.19.2. Financial Performance
- 11.19.3. Product Benchmarking
- 11.19.4. Recent Development
